This program was developed by Dr. Steven Bloom and Dr. Harry Gottlieb, of the Medical College of Pennsylvania, in conjunction with Exhibit Technology, Incorporated, New York, New York. It is intended as a service from Pfizer, and is not meant to have any other educational or medicinal purpose. This program is based in part upon the following references: 1) Foster, D.F., McGarry, J.D. The Metabolic Derangements and Treatment of Diabetic Ketoacidosis. N Engl J Med 1983; 309: 159-169. 2) Kreisberg, R.A. Diabetic Ketoacidosis: New Concepts and Trends in Pathogenesis and Treatment. Ann Intern Med 1978; 88: 681-95. 3) Beigelman, P.M. Severe Diabetic Ketoacidosis (Diabetic "Coma"): 482 Episodes in 257 Patients; Experience of Three Years. Diabetes 1971; 20: 490-500. 4) Sherwin, R.S. et al. A Model of the Kinetics of Insulin in Man. J Clin Invest 1974; 53: 1481-1492. 5) Binder, C. Absorbtion of Injected Insulin. Acta Pharmacol Toxicol (Copenh) 1969; 27 (Suppl 2): 1-87. 6) Padilla, A.J., Loeb, J. "Low-Dose" Versus "High-Dose" Insulin Regimens in the Management of Uncontrolled Diabetes. Am J Mid 1977; 63: 843-848. 7) Adrogue, H.J. et al. Plasma Acid-Base Patterns in Diabetic Ketoacidosis. N Engl J Med 1982; 307: 1603-10.
